BioSpace News Archive

Kronos Bio, Inc. (Nasdaq: KRON) today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024.

BeiGene, Ltd., a global oncology company, announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology Annual Meeting in Chicago, May 31 - June 4, 2024.

Arvinas, Inc. announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer.

IO Biotech (Nasdaq: IOBT) today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.

STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024.

NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

NANOBIOTIX provided an update on operational progress and reported financial results for the year ended December 31, 2023, and announced the filing of its universal registration document for the financial year ended December 31, 2023 with the French financial market authority, as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2023 with the U.S. Securities and Exchange Commission.

Innovent Biologics, Inc. announces that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates as well as innovative drugs including TYVYT®, olverembatinib, taletrectinib from its oncology pipeline will be presented at the American Society of Clinical Oncology Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..